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Toxoplasma gondii is an Apicomplexan obligate intracellular protozoan parasite, 
which is able to infect virtually all warm-blooded animals.  According to the Centers for 
Disease Control approximately 60 million people in the U.S. are currently infected with T. 
gondii.  Treatments for toxoplasmosis are limited and generally consist of a combination of 
pharmaceuticals.  Based on the prevalence and limited options for treatment new drug 
targets should be explored.  Cell cycle proteins often present themselves as good drug 
targets.  TgCDK1 and TgCYC2 are cell cycle proteins.  TgCDK1 is a cyclin dependent kinase 
and TgCYC2 is thought to be a cyclin protein.  TgCDK1 and TgCYC2 are associated with the 
G2 to M phase regulation of the cell cycle.  Inhibition of the cell cycle would prevent the cell 
from proliferating ultimately eliminating T. gondii from the host.  TgCDK1 and TgCYC2 
proteins must first be purified and a kinase assay has to be run in order to determine the 
function of these two proteins.  Experimental approaches to the purification and 





































 I would first like to thank both of my parents and fiancée for their continuous 
support throughout all of my academic pursuits.  With out their support I would not be 
where I am today.  I would also like to thank my advisor Dr. Christopher Kvaal for his 
patience and guidance as well as all of the knowledge he has imparted to me through out 
this research project and my stay at St. Cloud State University.   
Dr. Timothy Schuh and Dr. Nathan Winter for their advice and support with my research 
project as well as to writing my thesis document.  Dr. Michelle Wagner who made being a 
TA enjoyable, and dare I say easy, as well as a valuable learning experience.  The 
undergraduate as well as graduate students who have helped me with my research: Arthur 
Isaacson, Brock Cash, Cody Aston, Sam Ellis and Stuart Fogarty.  I am grateful for their 
continuous support and help in completing my research project.  Lastly I would like to 
























Table of Contents 
List of Tables ............................................................................................................................................. 6 
List of Figures ........................................................................................................................................... 7 
CHAPTER 1: Introduction .................................................................................................................... 8 
 Historical Information ............................................................................................................ 8 
 Prevalence ................................................................................................................................... 8 
 Transmission .............................................................................................................................. 9 
 Medical Relevance ................................................................................................................. 10 
 Treatment and Drug Targets ............................................................................................. 10 
 Proteins of Interest ............................................................................................................... 12 
 Hypotheses ............................................................................................................................... 13 
 TgCDK1 and TgCYC2 ............................................................................................................ 13 
 TgCDK7, TgCYC1 and TgMAT1 ......................................................................................... 15 
 Codon Optimization .............................................................................................................. 16 
CHAPTER 2: Hypotheses ................................................................................................................... 24 
CHAPTER 3: Materials and Methods ............................................................................................ 25 
 Bacterial Transformation, Culturing and Induction ................................................. 25 
 SDS-PAGE .................................................................................................................................. 26 
 Protein Purification ............................................................................................................... 27 
 Kinase Assay ............................................................................................................................ 29 




CHAPTER 4: Results ............................................................................................................................ 37 
 Induction SDS-PAGE Gels.................................................................................................... 37 
 Growth Curves ........................................................................................................................ 42 
 Purification SDS-PAGE Gels ............................................................................................... 43 
 Kinase Assay ............................................................................................................................ 47 
CHAPTER 5: Discussion ..................................................................................................................... 49 


































List of Tables 
 
Table 1: Codon usage table for the TgCYC2 coding sequence ......................................... 17 
Table 2: Codon usage table for the TgCYC2 codon optimized sequence .................... 19 
Table 3: Codon usage table for the TgCYC1 coding sequence ......................................... 21 
Table 4: Codon usage table for the TgCYC1 codon optimized sequence .................... 22 
Table 5: SDS-PAGE gel reagents and volumes for stacking and resolving gels ........ 27 
Table 6: Buffer reagents and volumes used for protein purification ........................... 29 



















List of Figures 
Figure 1: pEXP17 TgIMC1 expression vector construct .................................................... 32 
Figure 2: pEXP TgCDK1 expression vector construct ........................................................ 33 
Figure 3: pEXP17 TgCDK7 expression vector construct ................................................... 34 
Figure 4: pGEX-6P-1 TgCYC2 expression vector construct .............................................. 35 
Figure 5: pGEX-6P-1 TgCYC1 expression vector construct .............................................. 36 
Figure 6: TgCYC2 and TgCYC1 37oC induction SDS-PAGE gel ......................................... 37 
Figure 7: TgCYC2 and TgCDK1 37oC induction culture SDS-PAGE gel ........................ 38 
Figure 8: TgCDK1 and TgCDK7 37oC induction culture SDS-PAGE gel ........................ 39 
Figure 9: TgCYC2 25oC induction culture SDS-PAGE gel ................................................... 40 
Figure 10: TgCYC2 15oC induction culture SDS-PAGE gel ................................................ 41 
Figure 11: Growth curves for bacterial induction cultures .............................................. 42 
Figure 12: SDS-PAGE purification gel of a 25oC TgCDK1 induction culture .............. 43 
Figure 13: SDS-PAGE purification gel of a 15oC TgCDK1 induction culture .............. 44 
Figure 14: SDS-PAGE purification gel of a 25oC TgCYC2 induction culture ............... 45 
Figure 15: SDS-PAGE purification gel of a 15oC TgCYC2 induction culture ............... 46 










CHAPTER 1: Introduction 
Historical Information 
 Toxoplasma gondii was first discovered in 1908 by scientists who were initially 
studying leishmania (Dubey, 2009).  T. gondii had first been discovered in Ctenodactylus 
gundi (Dubey, 2009).  C. gundi is a rodent that is found in northern Africa.  The genus name 
Toxoplasma was given due to the morphology of the parasite, which translates from Greek 
to mean, “arc shape” (Innes, 2010).  The species name is also derived from the species in 
which it was discovered, C. gundi.  Initially the asexual stages of T. gondii were only known 
and it was not until 1970 when its sexual stage was discovered (Dubey, 2009).    
Prevalence  
Toxoplasma gondii is an Apicomplexan obligate intracellular protozoan parasite, 
which is able to infect virtually all warm-blooded animals.  It is no wonder that T. gondii is 
considered to be one of the most successful parasites (Innes, 2010).  An estimated 16-40% 
of the population in the United States and the United Kingdom are infected with T. gondii 
(Hill and Dubey, 2002).  Estimates also show that up to one-third of the world’s population 
is infected with T. gondii (Tenter, Heckeroth and Weiss, 2000).  T. gondii is one of the most 
prevalent parasites worldwide (Pittman and Knoll, 2015).  The ability of T. gondii being 
able to infect a wide range of hosts, as well as its method of replication lead to the overall 
success of this parasite.  T. gondii replicates using endodyogeny, or multiple fission, in 
which a mother cell divides into two daughter cells.  Tachyzoite phase replicates a very 
high rate making it difficult for the host’s immune system to eliminate the parasite.              




The prevalence of the organism can be linked to the multitude of ways in which it can be 
transmitted.    
Transmission 
 The parasite is primarily transmitted in three ways: Consuming undercooked 
or raw meat containing tissue cysts or tachyzoites, ingesting oocyte contaminated soil or 
water, or through congenital transmission, mother to child (Tenter, Heckeroth and Weiss, 
2000).  T. gondii can also be transmitted through an organ transplant and in rare cases 
blood transfusions (Montoya and Liesenfeld, 2004).  In the United States the consumption 
of meat that contains either tachyzoites or tissue cysts is believed to be the number one 
route in transmitting    T. gondii, specifically through the consumption of pork (Tenter, 
Heckeroth and Weiss, 2000).  Cultural habits also play a factor in the acquisition of T. 
gondii.  In France the high transmission rate is believed to be due to cooking and eating 
habits whereas in Central America it is believed to be mainly due to environmental 
contamination (Hill and Dubey, 2002).  Even though there is a high transmission rate of T. 
gondii through out the world.  The disease does not always pose a threat to the host; 
however in those that have a compromised immune system the disease can cause sever 
symptoms and even death.  This can be attributed to the rapidly dividing cells.  The host’s 
immune system, which is hindered, is not able to eliminate the parasite effectively.  This 
allows for the parasite to divide unchecked, which in turn results in the lyses of the host’s 
cells leading to damaged tissues.  This becomes a serious issue when the parasite invades 






Medical Relevance  
T. gondii is the causative agent of the disease toxoplasmosis.  Generally individuals 
infected with T. gondii are asymptomatic.  When symptoms do arise, for individuals who 
are immunocompetent, they typically resemble flu like symptoms. However, toxoplasmosis 
can cause severe neurological infections in patients with compromised immune systems 
(Jones et al., 2001).  Individuals with an autoimmune disease, that have contracted 
toxoplasmosis, will generally need to have pharmaceutical treatments over their lifespan.  
This is due to the potential of relapse from halting the treatment.  Symptoms for 
immunocompromised individuals tend to be more severe.  Encephalitis is the most 
common symptom among AIDS patients and generally forms abscesses in the brain if not 
treated (Montoya and Liesenfeld, 2004).  Toxoplasmosis infection accounts for roughly ten 
percent of deaths in AIDS patients (Innes, 2010).  Congenital transmission of    T. gondii can 
also cause severe disorders in the fetus.  Congenital transmission can lead to blindness, 
mental retardation and in some cases even death (Jones et al., 2001). However, these 
symptoms are dependent upon the trimester of the pregnancy in which toxoplasmosis is 
contracted by the fetus (Montoya and Liesenfeld, 2004).  Just as the severity of the 
symptoms is inversely related to the trimester in which the fetus contracts toxoplasmosis 
so is the occurrence of death.  If the fetus contracts toxoplasmosis in the first and second 
trimester there is a five to two percent chance it will result in the death or stillbirth for the 
fetus respectively (Montoya and Liesenfeld, 2004).   
Treatment and Drug Targets 
Treatment for toxoplasmosis generally consists of a combination of pharmaceuticals 




pharmaceuticals in which are prescribed, as well as the duration of the treatment, is 
dependent upon the demographics of the patient.  These pharmaceuticals will eliminate 
tachyzoites present, but they are not able to target the cysts.  The cells inside these cysts 
are still able to replicate and eventually rupture and spread to other tissues in the host.  
There is also no vaccine currently available for human use (Pittman and Knoll, 2015).  
There was also some controversy revolving around a pyrimethamine drug labeled 
Daraprim, which had jumped in price from around $13.00 to $750 dollars per pill.  Based 
on the limited options for treating toxoplasmosis, as well as there is no vaccine available 
shows that there is a need to develop new drug treatments.  In order to develop a drug 
treatment drug targets must first be identified.  
Cell cycle proteins tend to present themselves as prime drug targets as inhibition of 
these proteins can lead to the arrest of the cell cycle.  T. gondii as well as other 
microorganisms cause disease by cellular replication.  The parasite invades the host’s cells, 
and then undergoes replication.  Eventually the host’s cell will rupture and it is through this 
process, cellular lysis, which causes the disease.  This invokes an immune response as well 
as inflammation to the tissue(s) in which the parasite has invaded.  Cellular division is 
linked and controlled by the cell cycle and in turn by cell cycle regulators.  Many of the cell 
cycle regulators are conserved amongst Eukaryotes especially CDKs.  These proteins, CDKs, 
are highly conserved amongst Apicomplexans as well as Eukaryotes.  When it comes to 
cyclin proteins, the binding partner that activates CDKs, this is where Apicomplexans 
diverge from other Eukaryotes.  The TgCYC1 and TgCYC2 genes are not human cyclinB, nor 
cyclinH orthologs.  When looking at domains present within the Toxoplasma CYC1 and 




similar function.  Both CYC1 and CYC2 were determined to be interactors of CDK1 through 
yeast two-hybrid screening.  The fact that there is some similarity to other Eukaryotic 
cyclins and that it was experimentally determined to interact with a CDK tends to point 
towards being a cyclin like protein, however when analyzing the CYC1 and CYC2 sequence 
the MRAIL motif is absent from both sequences.  The MRAIL motif plays a role in substrate 
binding.  This indicates that CYC1 and CYC2 are divergent from other Eukaryotic cyclins 
and may present themselves as drug targets as there is less of a risk for cross reactivity 
with human cyclins.  
Proteins of Interest 
 The five proteins of interest are Toxoplasma gondii cell cycle proteins.  These 
proteins are involved with the regulation of the cell cycle.  The proteins are as follows: 
TgCDK1, TgCDK7, TgCYC1, TgCYC2 and TgMAT1.  The CDKs are cyclin dependent kinases, 
which are involved in the phosphorylation of specific substrates.  The act of 
phosphorylation and dephosphorylation will either activate or inactivate substrates.  
Through this process of inactivation or activation the cell cycle progresses.  In order for a 
CDK to be active it must be bound with its cyclin binding partner.  TgCYC1 and TgCYC2 are 
cyclin like proteins, and may potentially be the cyclin partner of TgCDK7 and TgCDK1 
respectively.  TgMAT1 is a mediator protein that could potentially facilitate the formation 
of a CAK, cyclin dependent kinase activating kinase.  The CAK is involved in 
phosphorylating the activation loop of a CDK-cyclin complex, and thus activating that 
complex.  The goal for the experiment is to determine the function of each of these proteins 




understanding of the cell cycle, and the proteins involved with the regulation of the cell 
cycle of Toxoplasma gondii.   
Hypotheses 
 Hypothesis 1 states that TgCYC2 will be an activator of TgCDK1.  This would point 
towards TgCYC2 acting in the capacity of a cyclin like protein, where the CDK is able to 
phosphorylate specific substrates, and thus progressing the cell cycle.   
Hypothesis 2 states that TgCYC2 will act as an inhibitor of TgCDK1.  This would point 
towards the formation of the TgCDK1-TgCYC2 complex to inhibit the kinases activity in 
phosphorylating specific substrates to TgCDK1.  Hypothesis 3 states that TgCYC2 will not 
affect the activity of TgCDK1.  This hypothesis can be simply explained by looking at a 
result generated by a yeast two-hybrid screen.  The result showed that TgCYC2 was a 
strong interactor of TgIMC1.  TgIMC1, inner membrane complex 1, is involved in the 
formation of developing daughter cells with in the mother cell.  IMC1 is specifically 
involved with the formation of the membrane of the daughter cells.  This result point 
towards the possibility of TgCYC2 being a targeting molecule, in that it localizes TgCDK1 to 
the inner membrane complex and the developing daughter cells.   
TgCDK1 and TgCYC2 
TgCDK1 (Wastling and Kinnaird, 1998) coding sequence (TGVEG_218220) shows 
homology to PKc superfamily of proteins.  TgCDK1 has five notable domains throughout 
the amino acid sequence: ATP binding site, active site, substrate binding site, CDK/cyclin 
interface and an activation loop.  These domains encompass many residues throughout 
amino acid sequence.  Active site regions occur at residues: 10-13, 18, 30, 32, 49, 63, 79-82, 




regions occur at residues: 10-13, 18, 30, 32, 63, 79-82, 85, 88, 129-130, 132 and 143.  The 
activation loop occurs at residues 142-153, 156-165.  The e value associated with both the 
PKc_like superfamily and the STK_like_CDK protein hits were 0.  Superfamilies of proteins 
are groupings of proteins that share homology between proteins found many organisms.  
They tend to have similar functions and structures.  STK is a superfamily of serine 
threonine kinases and PKc is a superfamily of protein kinases.  The primary function of a 
protein kinase or serine threonine kinase is to phosphorylate specific substrates.  The e 
value determines the probability that the protein family hits were due to random chance, 
so an e value of 0 means that it was not due to random chance.  Based on the e values for 
the hits for the protein families and the domains present with in the TgCDK1 amino acid 
sequence, it appears to be a cyclin dependent kinase like protein.  TgCDK1 also shares 
homology with human CDK1, which plays a role in G2 to M phase regulation of the cell 
cycle.  
TgCYC2 (TGVEG_290020) has been experimentally determined to be an interactor 
of TgCDK1 (unpublished data, Kvaal).  The data for TgCYC2 being an interactor of TgCDK1 
was generated through the use of a yeast-two hybrid screening system.  Upon analyzing the 
protein sequence of TgCYC2 a cyclin box fold domain appears between residues 789-843.  
This supports the idea that TgCYC2 is an interactor of TgCDK1.  The function of TgCYC2 for 
the cell cycle has yet to be determined.  However, the overexpression of TgCYC2 leads to 
cell cycle arrest in S.cerevisiae (Wade-Ferrell, 2011).  This suggests that TgCYC2 could be a 






TgCDK7, TgCYC1 and TgMAT1 
 TgCYC1 (TGVEG_260250) when looking at domains present in the amino acid 
sequence a cyclin box fold appears between residues 126-204 and has binding sites at 
residues 170, 174, 183, 199 and 202-203.  TgCYC1 has also been experimentally 
determined to interact with TgCDK1 as well as recover a CLN2 S. cerevisiae mutant (Kvaal, 
Radke, Guerini and White 2002).  TgCYC1 is thought to be a cyclin H ortholog. This was 
determined through bioinformatics analysis of the amino acid sequence, specifically an 
alignment between TgCYC1, P. falciparum CYC1 and H. sapien Cyclin H (Kvaal et al., 2002). 
TgMAT1 (TGVEG_320070) based on the analysis; belongs to the RING-finger group of 
proteins.  There is a RING-finger domain that occurs between residues 6-60. TgMAT1 also 
has a cross-brace motif, which occurs at residues: 6, 9, 27, 29, 32, 35, 53 and 56.  TgMAT1 
also came back with a CDK-activating kinase assembly factor hit.  Based on this data 
TgMAT1 appears to be a MAT1 ortholog, which will play a part in assembling the CAK 
molecule.  TgCDK7 (TGVEG_270330), when analyzing the sequence, appears to belong to 
the PKc superfamily of proteins and is a STK_CDK like protein.  TgCDK7 has ATP binding 
sites through out the protein sequence.  The residues at which the ATP binding site appears 
are as follows: 58-61, 64, 66, 139, 155-158, 200, 204-205, 207 and 217-218. CDK7 and 
CYC1 when bound with MAT1 form the CAK, which can phosphorylate the activation loop 
of other CDK molecules, and thus activating the CDK-cyclin complex.  Data that supports 
these three proteins interacting with one another (TgCYC1, TgCDK7 and TgMAT1) was 
generated through the use of a yeast two-hybrid screening system.  TgMAT1 and TgCYC1 






 Rare codon usage was apparent in the coding sequences of TgCYC1 and TgCYC2, this 
had been determined by a previous graduate student (Noyes, 2013).  Both the TgCYC1 and 
TgCYC2 sequences were subsequently optimized using alternative codons.  The codons that 
had been chosen are far more prevalent with in E. coli’s genome, thus making more likely 
that E. coli has a tRNA for the codons in question.  This ultimately leads to the greater 




















Table 1: Codon usage table for the TgCYC2 coding sequence. 
 
TgCYC2 Coding Sequence 





GCA 0 CCA 2 
GCT 6 CCT 5 
GCC 10 CCC 3 
Cys TGT 2 Gln CAG 12 TGC 4 CAA 5 
Asp GAT 1 
Arg 
AGG 3 
GAC 8 AGA 7 
Glu GAG 6 CGG 4 GAA 11 CGA 4 





GGA 2 AGC 4 
GGT 3 TCG 7 
GGC 11 TCA 1 





ATT 3 ACA 2 
ATC 3 ACT 3 




TTG 2 GTA 0 
TTA 1 GTT 2 
CTG 7 GTC 7 
CTA 0 Trp TGG 1 
CTT 6 Tyr TAT 1 CTC 20 TAC 7 
Met ATG 9 
Stop 
TGA 1 





The coding sequence found in Table 1 was constructed using accession number 
ABM92262.1, which is an experientially determined interactor of TgCDK1.  An alignment 
was done with the ABM92262.1 amino acid sequence and TGVEG_290020 amino acid 
sequence.  The residues in which the sequences aligned were used to determine the coding 
sequence for TgCYC2 using TGVEG_290020 as a reference.  The shaded cells in the table 





















Table 2: Codon usage table for the TgCYC2 codon optimized sequence. 
 
TgCYC2 Optimized Sequence 





GCA 10 CCA 2 
GCT 5 CCT 3 
GCC 5 CCC 1 
Cys TGT 4 Gln CAG 10 TGC 2 CAA 7 
Asp GAT 6 
Arg 
AGG 0 
GAC 4 AGA 0 
Glu GAG 4 CGG 2 GAA 13 CGA 0 





GGA 5 AGC 5 
GGT 4 TCG 3 
GGC 6 TCA 5 





ATT 5 ACA 1 
ATC 1 ACT 2 




TTG 3 GTA 3 
TTA 6 GTT 4 
CTG 17 GTC 8 
CTA 0 Trp TGG 1 
CTT 3 Tyr TAT 5 CTC 7 TAC 3 
Met ATG 9 
Stop 
TGA 0 




The sequence used to generate Table 2 was genetically engineered to limit or 
eliminate rare codons found in the TgCYC2 coding sequence.  This in turn increases the 


















Table 3: Codon usage table for the TgCYC1 coding sequence. 
TgCYC1 Coding Sequence  





GCA 13 CCA 7 
GCT 17 CCT 9 
GCC 14 CCC 6 
Cys TGT 2 Gln CAG 11 TGC 11 CAA 14 
Asp GAT 6 
Arg 
AGG 5 
GAC 21 AGA 5 
Glu GAG 36 CGG 15 GAA 32 CGA 7 





GGA 7 AGC 10 
GGT 5 TCG 14 
GGC 10 TCA 5 





ATT 8 ACA 6 
ATC 9 ACT 2 




TTG 11 GTA 1 
TTA 0 GTT 11 
CTG 20 GTC 12 
CTA 3 Trp TGG 5 
CTT 8 Tyr TAT 1 CTC 14 TAC 2 
Met ATG 6 
Stop 
TGA 0 
Asn AAT 3 TAG 1 AAC 10 TAA 0 
 
The sequence used to generate Table 3 was received from accession number 




Table 4: Codon usage table for the TgCYC1 codon optimized sequence. 
TgCYC1 Optimized Sequence 





GCA 24 CCA 5 
GCT 10 CCT 6 
GCC 20 CCC 4 
Cys TGT 8 Gln CAG 17 TGC 6 CAA 4 
Asp GAT 16 
Arg 
AGG 0 
GAC 10 AGA 0 
Glu GAG 19 CGG 5 GAA 43 CGA 0 





GGA 4 AGC 16 
GGT 11 TCG 10 
GGC 9 TCA 9 





ATT 7 ACA 2 
ATC 10 ACT 2 




TTG 8 GTA 2 
TTA 5 GTT 8 
CTG 37 GTC 5 
CTA 0 Trp TGG 5 
CTT 5 Tyr TAT 1 CTC 2 TAC 2 
Met ATG 6 
Stop 
TGA 1 





The sequence used to generate Table 4 was also genetically engineered to limit or 
eliminate rare codons found in the sequence.  The optimization was accomplished through 
























CHAPTER 2: Hypotheses 
H01: TgCYC2 will act as an activator of TgCDK1 
H02: TgCYC2 will act as an inhibitor of TgCDK1 























CHAPTER 3: Materials and Methods 
Bacterial Transformation, Culturing and Induction 
Two strains of E. coli were used for the transformations: BL21 and BL21 AI.  For 
TgCYC2 and TgCYC1, which were cloned into the pGEX-6p vector, Bl21 cells were used.  
TgCDK1, TgIMC1 and TgCDK7, which were cloned into the pDEST17 vector, BL21 AI cells 
were used.  Different strains were used based upon the promoter that was used for each 
plasmid.  BL21 AI uses T7 based promoter system, and BL21 uses a non-T7 based promoter 
system.  The respective cells were removed from the -80oC and put on ice to thaw.  Once 
the cells had thawed 50ng of the appropriate plasmid was added to the E. coli cells.  The 
solution was gently mixed then centrifuged, using a minifuge, at 6,000 RPM for 1 second 
and then placed on ice.  The plasmid and cells were allowed to incubate on ice for 15 
minutes.  The cells were then heat shocked, using a dry bath, for 45 seconds at 42oC.  
Immediately after SOC was added to a final volume of 1ml.  SOC media is an extremely 
nutrient rich media, that allows for the bacterial cells to recover prior to plating them.  
Allowing for the bacterial cells to recover greatly increases the transformation efficiency.  
The cells were then incubated for 10-15 minutes at 37oC, shaking at 250 RPM.  The cells 
were then plated onto solid agar LB + ampicillin media and spread using glass beads. LB 
media is a nutrient rich media, which is used for bacterial growth.  Ampicillin is the 
selectable marker for both of the plasmids, which determines if the bacteria have been 
successfully transformed.  Plates were then placed into an incubator set to 37oC overnight.   
Once colonies had formed, a single uniform colony was plucked and used to 
inoculate liquid LB + ampicillin media.  The cultures were either grown up at 37oC, 25oC or 




control.  The cultures containing the plasmid with the positive control were grown up in 
concert with the experimental cultures.  The cultures were grown until they had reached an 
OD600nm of 0.8-1.2.  Once the desired OD600nm had been reached the cultures were induced.   
To induce BL21 cells 1ul of 1M IPTG was added per ml of bacterial culture.  BL21 AI cells 
were induced using the same method for BL21 cells, however 10ul of a 20% arabinose 
solution was also added per ml of bacterial culture.  Prior to adding the inducing agents 
BL21 AI cells were washed with glucose free media.  The wash steps involved repeated 
centrifugations at 6,000 RPM for 10 minutes at 4oC and then resuspending the pellet in 
glucose free media.  These steps were repeated for a total of three times to remove the 
glucose from the culture.  BL21 AI cells are under the control of another regulator, which is 
inhibited in the presence of glucose.  Expression is turned on by the absence of glucose and 
or the presence of arabinose.  The amount of time for which the cultures were induced was 
based upon the induction temperature.  The cultures grown at 15oC, 25oC and 37oC were 
induced for 1-2, 2-3 and 4-6 hours respectively, or until the culture had reached an OD600nm 
of 1.6-1.8.  Prior to spinning down the cells part of the culture was removed and used to 
run an SDS-PAGE gel.  After the induction the cells were pelleted at 6,000RPM at 4oC for 5 
minutes and then stored at -80oC.   
SDS-PAGE 
 SDS-PAGE gels were used for verification of protein expression and for verification 
for protein purification.  A resolving gel of 10% was used for all of the SDS-PAGE gels.  The 
recipe for all SDS-PAGE gels can be seen below in Table 5.  The resolving gel was prepared 
first using the reagents in Table 5.  The temed was the final reagent added, which initiated 




prepared using the reagents in Table 5.  The gel was run at 80 volts through stacking gel.  
Once the samples had loaded into the resolving gel the voltage was increased to 110 volts.  
The SDS-PAGE gel post induction was run using a sample of the pellet, which was boiled.  
Uninduced and induced cultures we added to separate lanes to determine if any induced 
bands were present in the gel.  IMC1 acted as the positive control and was used to ensure 
the induction was successful.  
Table 5: SDS-PAGE gel reagents and volumes for stacking and resolving gels. 
Stacking Gel 
Reagent  Volume 
H2O 4.8ml 
0.5M Tris pH 6.8 2ml 
10% SDS 80ul 




Reagent  Volume 
H2O 9.6ml 
1.5M Tris pH 8.8 5ml 
10% SDS 200ul 





 The proteins of interest were purified using ion exchange and affinity 
chromatography.  The components for each of the buffers used for protein purification are 
listed below in Table 6.  The 6xHis tagged proteins were purified using nickel agarose 




manufacturers protocols).  The pellets, generated from the induction, were first 
resuspended in lysis buffer and then lysed using sonication.  The resuspended cells were 
placed on ice and were sonicated for 20 minutes at intervals of 15 seconds on and 60 
seconds off at 40% amplitude.  They were purified using batch purification method.  For 
batch purification the sample is incubated with the beads in a container, conical tube or 
micro centrifuge tube.  This is an alternative method to column chromatography, where the 
sample incubates on the beads in a cylindrical column.  The crude lysate was centrifuged 
for 60 minutes at 11,800xg at 4oC.  The clarified lysate was then incubated on the beads for 
one hour at 4oC on an oscillating rocker.  The beads were then centrifuged at 700xg for 2 
minutes and the supernatant was collected.  After the incubation the beads were then 
repeatedly washed using the wash buffer.  The volume of the wash buffer was 2 times that 
of the resin bed volume.  The resin bed volume refers to the volume of the chromatography 
beads.  After each wash step the beads were centrifuged at 4oC for 2 minutes at 700xg.  The 
supernatant from each wash step was pipetted off and stored at -80oC.  The proteins were 
then eluted using elution buffer, which contained either L-glutathione or imidazole.  The 
elution volume was the same volume as the resin bed volume.  The beads were centrifuged 
at 4oC for minutes at 700xg and the supernatant was collected and stored at -80oC.  The 
crude protein concentration was determined through the use of a spectrophotometer 








Table 6:  Buffer reagents and volumes used for protein purification. 
6xHis Tag Purification 
Buffer Type Buffer Reagent Reagent Molarity 















GST Tag Purification 
Buffer Type Buffer Reagent Reagent Molarity 
Lysis Buffer                  














L-Glutathione 10, 50 and 100mM 
 
Kinase Assay 
 The Kinase Glo Plus™ kit (Promega) was used in order to assay the enzymatic 
activity of TgCDK1 alone as well as in the presence of TgCYC2.  The positive control was 
human CDK1 and cyclin B.  The substrate was histone H1, which is a known substrate for 







Table 7:  Kinase assay reaction matrix. 
 
Total Reaction Volumes for Kinase Assay 
Assay 














10ul 10ul 10ul 10ul 10ul 10ul 
ATP 2ul 2ul 2ul 2ul 2ul 2ul 
Histone 
H1 2ul 2ul 2ul 2ul 2ul 2ul 
TgCYC2 2ul   2ul 4ul 9ul 
TgCDK1  1ul  1ul 1ul 1ul 
Positive 









10ul 10ul 10ul 10ul 10ul 10ul 
ATP 2ul 2ul 2ul 2ul 2ul 2ul 
Histone 
H1       
TgCYC2 2ul   2ul 4ul 9ul 
TgCDK1  1ul  1ul 1ul 1ul 
Positive 




14ul 13ul 14ul 15ul 17ul 22ul 
 
Volumes for the reagents added to each well in the 96 well plate.  RA stands for the 
wells containing only the Kinase Glo Plus™ buffer and ATP, along with TgCYC2, TgCDK1 and 
or the positive control.  RAH is the same as RA, however the substrate histone H1 has also 
been added to the wells.  TgCYC2 alone is to ensure that it does not have any intrinsic 
enzymatic activity and TgCDK1 alone is to determine its intrinsic enzymatic activity.  The 
last three sets of wells were the experimental wells.  TgCYC2 concentration was increased 




buffer, which was reconstituted luciferase and luciferin, was also added to each of the wells 
and was constant in the volume in which it was added.  ATP was also added at a constant 
volume to each well.  ATP was the energy source for the kinase assay.  ATP provided the 
phosphate to phosphorylate the substrate histone H1.  The remaining ATP, not used by the 
CDK-cyclin complex phosphorylating the substrate, was used up by the luciferase enzyme.  
The resultant reaction, generated by the luciferase enzyme, produced a photon, which was 
perceived as light.  The levels of luminescence are inversely proportional to the kinase 
activity.  The higher the luminescence levels the lower the activity of the CDK-cyclin 
complex and lower luminescence levels correlate to higher CDK-cyclin activity.  The 
reaction was allowed to incubate at 35oC for 10 minutes.  The 96 well plate was then placed 
in a luminometer.  The results collected from the luminometer read out were used to 















Expression Clone Constructs 
 
 
Figure 1:  pEXP17 TgIMC1 expression vector construct. 
The TgIMC1 gene was recombinantly cloned into the pEXP17 expression vector.  
The expression vector uses a T7 promoter system and has an ampicillin selectable marker.  





Figure 2: pEXP TgCDK1 expression vector construct. 
TgCDK1 was cloned using recombination-cloning method into pEXP17 vector.  This 
sequence also has a 6xHis fused tag.  The selectable marker is ampicillin and the vector 





Figure 3: pEXP17 TgCDK7 expression vector construct. 
TgIMC1 was cloned using recombination-cloning method.  TgIMC1 also has 6xHis 
fused tag and uses ampicillin as the selectable marker.  This vector also uses a T7 promoter 





Figure 4: pGEX-6P-1 TgCYC2 expression vector construct. 
TgCYC2 was cloned into this vector using restriction-cloning method.  BamHI and 
SalI were the recognition sites used for cloning.  This expression system uses a tac 
promoter system and uses ampicillin as the selectable marker.  There is also a GST fused 





Figure 5: pGEX-6P-1 TgCYC1 expression vector construct. 
TgCYC1 has a GST fused tag with a protease cleavage site.  This vector uses 










CHAPTER 4: Results 
Induction SDS-PAGE Gels 
 
Figure 6: TgCYC2 and TgCYC1 37oC induction SDS-PAGE gel. 
The gel was run using boiled pellet samples from each of the induction cultures.  The 
induction was run at 37oC.  Based on the image neither of the proteins of interest were 
expressed.  The positive control had worked, as an induced band is visible at the 75kD 
marker in the gel.  The expected molecular weights (MW) for TgCYC1 and TgCYC2 were 
90kD and 50kD respectively.  The boxes outlining bands with in the gels indicate induced 





Figure 7: TgCYC2 and TgCDK1 37oC induction culture SDS-PAGE gel. 
The samples consisted of boiled pellets.  The cultures were induced at 37oC.  Neither 
TgCDK1, nor TgCYC2 were expressed under the experimental conditions.  There were no 
visibly induced bands at the MW markers for TgCYC2 (50kD), nor TgCDK1 (37kD) 
confirming the expression was unsuccessful.  There is however a visibly induced band at 
the 75kD marker for IMC1.  IMC1 was successfully expressed showing that the experiment 






Figure 8: TgCDK1 and TgCDK7 37oC induction culture SDS-PAGE gel. 
The samples loaded in the wells were again from boiled pellets.  The cultures were 
induced at 37oC.  There was no band visible in the TgCDK7 induced lane, which means that 
the protein was not expressed.  The expected MW for TgCDK7 is 49kD.  A sample from a 
TgCDK1 induction culture was added to use as a comparison to the TgCDK7 induced 




debris, which is why the lane appears a single smear.  The induction had worked based on 
the induced band appearing in the IMC1 induced lane at the 75kD marker.      
 
 
Figure 9: TgCYC2 25oC induction culture SDS-PAGE gel. 
The samples used were boiled pellets of induced and uninduced TgCYC2 cultures.  
The induction was run at 25oC.  TgCYC2 was expressed at 25oC. There is a band visible at 
the 50KD MW marker, which does not appear in the uninduced culture.  IMC1 was also 






Figure 10: TgCYC2 15oC induction culture SDS-PAGE gel. 
This gel image was generated using samples of boiled pellets from the induction 
cultures.  The induction was run at 15oC.  Same as in the TgCYC2 25oC culture, there is a 




IMC1 was also expressed showing that the induction was successful.  There was very little 
difference in the intensity and observed density of the induced bands produced by the 25oC 
and 15oC induction cultures.   
Growth Curves 
 
Figure 11: Growth curves for bacterial induction cultures. 
The cultures were grown up and induced at 37oC, 25oC and 15oC.  The growth curves 
indicate the time it took for each culture to reach the optical density (OD) in which they 
were induced.  All the cultures were induced between an OD600nm of 0.8-1.2 the cultures 
were then grown till an OD600nm of 1.6-1.8 was reached.  The cultures were then harvested 


























Purification SDS-PAGE Gels  
 
Figure 12: SDS-PAGE purification gel of a 25oC TgCDK1 induction culture. 
The induction culture was grown at 25oC.  Based on the gel image TgCDK1 appears 
to have been purified.  The wash steps the band at 37kD disappears and reappears in the 
eluate. One reasoning for this is it could be that the beads had been over-loaded with 
protein, or it had exceeded the binding capacity of the beads.  The eluate sample was also 






Figure 13: SDS-PAGE purification gel of a 15oC TgCDK1 induction culture. 
The induction culture had been grown at 15oC.  There are faint bands in both of the 
eluate samples.  These bands that appear in both elution samples line up just below the 
37KD MW marker, which is the predicted MW of the 6xHis tagged TgCDK1 protein.  
TgCDK1 was also expressed and purified at 25oC (Figure 12).  There are multiple bands 








Figure 14: SDS-PAGE purification gel of a 25oC TgCYC2 induction culture. 
The culture was induced at 25oC.  Based on the gel image TgCYC2 was not purified, 







Figure 15:  SDS-PAGE purification gel of a 15oC TgCYC2 induction culture. 
The culture was induced at 15oC.  There is no band visible in either of the elution 
lanes, however a very distinct band appears at the 50kD marker in the clarified lysate.   
Based on the results from the SDS-PAGE gels protein expression was exhibited from 
cultures induced at 25OC and 15oC.  Cultures that were induced at 37oC did not exhibit any 
protein expression for the proteins of interest.  TgCYC1 and TgCDK7 were altogether 
unable to be expressed under any of the conditions.  TgCDK1 and TgCYC2 were expressed 
at both 25oC and 15oC.  TgCDK1 was purified based on the results from the SDS-PAGE gel 
images as there are bands appearing just below the 37KD MW marker in both purification 
gels.  Based on the gel images TgCYC2 was unable to be purified.  The protein was seen in 
the gel image from the boiled pellet, which is Figure 10.  A band at the 50kD is also visible 
in the clarified lysate in Figure 15.  Based on the gel images from the protein purifications a 






Figure 16: Preliminary kinase assay. 
Contained with in the wells indicated by the black bars was as follows: the Kinase 
Glo Plus™ buffer solution (Promega) containing luciferase and luciferin substrate and ATP.  
Contained with in the wells indicated by the white bars was as follows: The Kinase Glo 
Plus™ buffer solution (Promega) containing luciferase and luciferin substrate, ATP and 
Histone H1.  The solutions contained with in the wells indicated, as black bars were to 
control for the maximum amount of ATP possible with in the samples. Essentially the 
solutions without Histone H1 should have produced the maximum amount of light for that 
trial.  The wells containing histone H1 should have not produced more relative light units 























only TgCYC2, had shown higher RLU values in the wells containing histone H1 than in the 
wells with out histone H1.  This could have been due to impurities present in the eluate 
samples.  This could also be resultant from the different volumes for each of the wells in the 
96 well plate.  Table 7 depicts the volumes for each of the wells in the 96 well plate.  The 
difference in volumes for the wells was due to the increasing volume of protein samples.  
The volumes could have been normalized by simply adding more elution buffer to each of 




































CHAPTER 5: Discussion 
 
Three of the five proteins of interest were expressed: TgCYC2, TgCDK1 and TgIMC1.  
Of those three proteins of interest only TgCDK1 was purified however, based on Figures 11 
and 12 the samples were impure.  TgCYC1 and TgCDK7 were unable to be expressed based 
on the SDS-PAGE gels.  It was evident that the bacteria were transformed with the plasmid 
containing the gene of interest for both of these proteins, as they were able to grow in LB 
media containing ampicillin.   
 Based on the results obtained from 37oC cultures it was elected to grow up and 
induce at lower temperatures.  The rationale for lowering the temperature is  that in doing 
so the expression level of proteins is lowered.  Lowering expression levels will ultimately 
lead to a lower concentration of the recombinantly expressed protein as well as native 
protein expression with in the cell.  This aids in alleviating any toxic effects the 
recombinantly expressed protein may enact upon the cell as well as decrease the chances 
of inclusion body formations.  Temperatures between 25oC and 15oC can prevent inclusion 
bodies from forming (San-Miguel, Pérez-Bermúdez, Gavidia, 2013).  Inclusion bodies are 
aggregates of proteins, which are generated through unwanted protein-protein 
interactions causing the protein to become insoluble.  TgCYC1 and TgCYC2 both had a fused 
GST tag, which in design increases the solubility of the proteins being expressed. However, 
the mechanism or reason for the increased solubility has yet to be determined (Rosano and 
Ceccarell, 2014).  GST is also readily expressed in E. coli and would hopefully force the 
expression of the cyclins.  Expressing proteins at lower temperatures also allows for proper 
folding of proteins.  These changes made to the methodology hopefully would lead to a 




 The cultures that were grown up and induced at 25oC and 15oC provided the best 
results.  TgCDK1, TgCYC2 and TgIMC1, which were the only three proteins of interest 
attempted at these temperatures, were successful.  The attempts for purification were 
mixed as only TgCDK1 was purified.  TgCYC2, which was expressed at 25oC and 15oC, was 
unable to be purified.  This result was unexpected, as the protein had appeared at the 
50kDa MW marker, which is where it was expected.  This ultimately means the protein was 
still fused to the GST tag.  When looking at the purification gel, the protein is appearing in 
the clarified lysate, not in the eluate.  In other words the protein is appearing in the soluble 
fraction, which indicates the protein is not segregated to inclusion bodies.  The protein 
should have been readily purified through the use of glutathione beads.  One possible 
explanation for lack of purification is the inability of the folding of the protein, which may 
interfere with the GST binding to the beads.  
TgCDK1 was purified from both 25oC and 15oC induction cultures.  There are bands 
appearing in the eluate just below the 37kDa marker in Figures 12 and 13.  Upon analyzing 
the gels the elution samples were not very pure.  These samples were contaminated with 
other native E. coli proteins.  This could lead to issues when running a kinase assay, as 
there could potentially be cross reactivity with the proteins native to E. coli present in the 
eluate.  Figure 12 appears to be a cleaner sample when comparing to Figure 13, however 
bands that were no longer visible in wash 3 reappear in the eluate.  These bands, apart 
from the band at 37kDa are most likely due to non-specific binding.  The purification 
process requires further optimization as the samples received from the elution are 
contaminated.  Adjusting the pH could lead to less non-specific binding due to the change of 




his-tag it would be beneficial to lower the pH.  When the pH is lower than the pI of a given 
protein that will lead to a protein with a net positive charge.  This in turn would result in 
less non-specific binding to the nickel beads, which have a positive charge.  Adjusting the 
ion concentration with in the buffer can also have a similar effect on non-specific binding.  
Because TgCDK1 was purified a preliminary kinase assay was run in order to determine its 
activity.   
The results generated from the kinase assay were inconclusive.  Upon analyzing 
Figure 16 there can be no definitive conclusions made pertaining to the effect TgCYC2 has 
on binding with TgCDK1.  The wells that had histone H1 versus the wells that histone H1 
was absent appears to be in reverse.  In other words the wells containing histone H1 
generated higher levels of luminescence when compared to the wells with out histone H1.  
The reason for why this is perplexing is simply due to the fact that the kinase activity, as it 
is perceived by the luminescence produced, should be relatively constant in the wells were 
histone H1 was absent.  When histone H1 is absent there is no substrate in which the 
kinase should be able to phosphorylate and therefore the amount of ATP should be the 
same pre and post incubation of the samples.  Therefore the levels of luminescence should 
remain at similar levels for all of the samples were histone H1 was absent.   
The kinase assay works by the luciferase enzyme using the remaining ATP 
contained with in the sample.  The ATP is used in the reaction of generating oxyluciferin 
from luciferin.  Upon the oxyluciferin relaxing from its excited state a photon is emitted and 
is perceived as light.  The levels of luminescence are proportional to the levels of remaining 
ATP, which is inversely related to the activity of the kinase.  This translates to the higher 




luminescence the higher the kinase activity.  When looking at Figure 16 the wells 
containing TgCYC2 and TgCDK1 there is a trend that as the concentration of TgCYC2 is 
increased the RLU also increases.  This suggests that as more TgCYC2 is added TgCDK1s 
activity is lowered, or is inhibited by the addition of TgCYC2.  When looking at the wells 
were histone H1 is absent however the result becomes unclear as the levels of 
luminescence are lower for those wells, and therefore appears to depict the kinase being 
more active in the wells were the substrate is absent.  The kinase uses the ATP present to 
phosphorylate a substrate, which in turn generates ADP and a product.  Once the ATP has 
been converted to ADP the luciferase enzyme can no longer generate oxyluciferin and 
therefore the levels of luminescence will be lower.  The only way in which the RLU can be 
lower is if the substrate is present.  This is why when looking at the wells containing 
TgCYC2 + TgCDK1 it is perplexing as the wells with histone H1 should be similar or lower 
to the wells in which histone H1 is absent.  The positive control depicts a similar result in 
that the samples containing histone H1 and the samples absent the substrate generated 
similar results.   
The positive control is human CDK1 and cyclinB, which was created for the use in 
kinase assays.  It is also important to note that histone H1 is a documented substrate of the 
human CDK-cyclin complex.  The result generated from the positive control requires much 
scrutiny, as it should have generated the expected results for each of the wells.  The levels 
of luminescence for the wells not containing histone H1 should have been higher than the 
wells with the substrate.  When looking at the Figure in reverse, flipping the samples 
around, the assay makes much more sense.  The wells with out the substrate would have 




TgCYC2 as an inhibitor of TgCDK1, which would support hypothesis 2.  TgCDK1 would also 
appear to have some intrinsic activity, which is supported by a study performed with P. 
falciparum Pfmrk.  Pfmrk had exhibited slight intrinsic enzymatic activity with out its cyclin 
partner present based on the results from the kinase assay (Chen et al., 2006).  This 
supports the possibility of the labeling of the wells having been flipped, which could simply 
be tested by running the kinase assay again with correctly labeled wells.   
After analyzing the results from the kinase assay it is clear that further optimization 
is needed.  Further optimization of the protein purification process is also needed, which 
could also affect the assay results especially if any of the contaminants affect the activity of 
the kinase, or CDK-cyclin complex.   
One consideration for further optimization of the kinase assay is the substrate that 
was used for the assay.  Histone H1 is a known substrate of human CDK1-cyclinB complex 
and should elicit kinase activity detectable by the assay.  A previous study looking at P. 
falciparum proteins found that when the substrate CTD was used, the Pfmrk activity was 
increased by up to two times, depending on if it was in complex with PfMAT1, compared to 
when histone H1 was used as the substrate (Jirage et al., 2010).  Perhaps a comparison 
between kinase activity in the presence of histone H1 and CTD would be a better 
determination of kinase activity for TgCDK1 and TgCDK1-TgCYC2.   
The experimentation completed herein defines a more effective way to induce 
expression of Toxoplasma proteins in E. coli.  This methodology should be broadly 
applicable to the growing number of proteins that are recognized in ToxoDB as cell cycle 
regulated.  By employing the techniques devised and developed it is conceivable that a 




proteins.  The TgCDK1/TgCYC2 interaction is but the first of the many interactions that are 
to be described and characterized in an effort to exploit the unique properties of the 
Toxoplasma cell cycle for drug development.  
As, such, the determination of the effect of TgCYC2 binding TgCDK1 is an important 
question to answer.  This answer will provide better insight into cell cycle regulation of 
Toxoplasma, and could also present a new drug target.  With the limited treatment options 
currently available for toxoplasmosis it is vital new drug targets to be discovered and 
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